YMAB Insider Trading Activity and SEC Form 4 Filings
YMAB insider trading summary
No open-market insider purchases or sales of Y-mAbs Therapeutics, Inc. (YMAB) have been reported on SEC Form 4 in the past 12 months.
Latest YMAB insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 7, 2025 | Michael J Rossi | President & CEO | Sell | $20K (3,917 @ $5.20) |
| Mar 7, 2025 | Thomas Gad | Chief Business Officer | Sell | $57K (10,810 @ $5.23) |
| Sep 16, 2024 | Thomas Gad | Chief Business Officer | Sell | $389K (30,000 @ $12.97) |
| Sep 13, 2024 | Thomas Gad | Chief Business Officer | Sell | $876K (65,000 @ $13.47) |
| Aug 28, 2024 | Torben Lund-Hansen | SVP & Chief Technical Officer | Sell | $769K (50,000 @ $15.37) |
| Aug 26, 2024 | Joris Wilms | SVP & Chief Operating Officer | Sell | $73K (5,000 @ $14.69) |
| Jun 11, 2024 | Thomas Gad | Chief Business Officer | Sell | $420K (35,000 @ $12.00) |
| Jun 10, 2024 | Thomas Gad | Chief Business Officer | Sell | $421K (35,000 @ $12.03) |
| Jun 10, 2024 | Gerard Ber | Director | Sell | $9K (722 @ $12.00) |
| May 31, 2024 | Bo Kruse | EVP, CFO, Secry & Treas. | Sell | $379K (31,371 @ $12.07) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.